All children received the same amount of diphtheria and tetanus toxoid
and associated alum adjuvant.
TETRAMUNE(R) Diphtheria and Tetanus Toxoids
and Pertussis Vaccine Adsorbed and Haemophilus b Conjugate Vaccine (Diphtheria CRM197 Protein Conjugate), the first combination vaccine to help prevent four serious childhood diseases with half the number of shots;
Adolescents aged 11 through 18 years who have completed the recommended childhood diphtheria and tetanus toxoids
and pertussis vaccine (DTP/DTaP) vaccination series should receive a single dose of Tdap instead of tetanus and diphtheria toxoids (Td) vaccine, preferably at a preventive-care visit at age 11 or 12 years (4).
The decision to create the stockpile was triggered by previous shortages of vaccines, including trivalent influenza vaccine (TIV), tetanus and diphtheria toxoids (Td), diphtheria and tetanus toxoids
and acellular pertussis (DTaP), and pneumococcal conjugate vaccine (PCV), a spokesman for the Department of Health and Human Services told this newspaper.
Aventis Pasteur is now producing Diphtheria and Tetanus Toxoids
and Acellular Pertussis Vaccine Adsorbed (DAPTACEL), which was recently licensed for the first four DTaP doses, and will continue to produce Tripedia as well.
HealthWire)--May 8, 1996--Wyeth-Lederle Vaccines and Pediatrics, a unit of Wyeth-Ayerst Laboratories, announced today that it has completed filing with the Food and Drug Administration a supplement for a new indication to the existing product license of its acellular pertussis vaccine, ACEL-IMUNE(R) Diphtheria and Tetanus Toxoids
and Acellular Pertussis Vaccine Adsorbed.
ACIP recommends a single Tdap dose for persons aged 11 through18 years who have completed the recommended childhood diphtheria and tetanus toxoids
and pertussis/diphtheria and tetanus toxoids
and acellular pertussis (DTP/DTaP) vaccination series and for adults aged 19 through 64 years (4,5).
Both the Chiron Biocine genetically engineered acellular pertussis vaccine and the chemically detoxified acellular pertussis vaccine in the Italian trial contain three Bordetella pertussis antigens: an inactivated form of pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN -- an outer membrane protein), combined with diphtheria and tetanus toxoids
Pertussis antibody concentrations for pertussis toxoid (PT), filamentous hemagglutinin (FHA), and pertactin in the first clinical trial were noninferior to those of infants after a primary diphtheria and tetanus toxoids
and acellular pertussis (DTaP) vaccination series with Infanrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) in a clinical trial in which efficacy of DTaP also was demonstrated (4-6).
On June 24, 2008, the Food and Drug Administration licensed a combined diphtheria and tetanus toxoids
and acellular pertussis adsorbed (DTaP) and inactivated poliovirus (IPV) vaccine, DTaP-IPV (Kinrix, GlaxoSmithKline Biologicals, Rixensart, Belgium).
On June 20, 2008 the Food and Drug Administration (FDA) licensed a combined diphtheria and tetanus toxoids
and acellular pertussis adsorbed (DTaP), inactivated poliovirus vaccine (IPV), and Haemophilus influenzae type b conjugate (tetanus toxoid [TT] conjugate) vaccine, DTaP-IPV/Hib (Pentacel, Sanofi Pasteur, Swiftwater, Pennsylvania), for use as a four-dose series in infants and children at ages 2, 4, 6, and 15-18 months (1,2).
For these children, the target is [greater than or equal to] 95% vaccination coverage for the following: hepatitis B vaccine; diphtheria and tetanus toxoids
and pertussis vaccine, diphtheria and tetanus toxoids
and acellular pertussis vaccine, or diphtheria and tetanus toxoids
vaccine (DTP/ DTaP/DT); poliovirus vaccine; measles, mumps, and rubella (MMR) vaccine; and varicella vaccine (1).